In an 86-year-old patient on dialysis who complains of insomnia, what medication should be prescribed?

Ramelteon 8 mg at bedtime or low-dose doxepin (3-6 mg) are the safest first-line pharmacologic options for this 86-year-old dialysis patient with insomnia.

Rationale for Medication Selection in Elderly Dialysis Patients

For this high-risk patient population (advanced age + dialysis), safety considerations must override typical first-line recommendations. While standard insomnia guidelines recommend benzodiazepine receptor agonists (BzRAs) as first-line therapy 1, the combination of advanced age and renal failure fundamentally changes the risk-benefit calculation.

Primary Recommendation: Ramelteon or Low-Dose Doxepin

Ramelteon 8 mg at bedtime is the optimal choice because 1, 2, 1:

• No dose adjustment required in renal failure 3
• No abuse potential or dependence risk
• Minimal cognitive/motor impairment in elderly patients
• Specifically addresses sleep-onset insomnia
• Non-scheduled medication (no controlled substance concerns)

Low-dose doxepin (3-6 mg) is the alternative first choice for sleep maintenance issues 2, 4, 5:

• FDA-approved specifically for sleep maintenance insomnia
• Lower anticholinergic burden at these doses compared to higher antidepressant doses
• Evidence supports efficacy in older adults 2
• However, requires careful monitoring in dialysis patients due to altered pharmacokinetics

Why NOT Standard BzRAs in This Patient

The 2017 AASM guidelines 2 suggest BzRAs (eszopiclone, zolpidem, zaleplon) and benzodiazepines (temazepam, triazolam) for general adult populations. However, critical safety concerns in an 86-year-old on dialysis include:

• Falls and fractures risk - observational data show serious injury associations 6
• Cognitive impairment and delirium risk - particularly problematic in elderly
• Altered pharmacokinetics in renal failure - though some agents like diazepam and midazolam are hepatically metabolized and considered "safe" in dialysis 3, the elderly are more sensitive to peak effects 7
• Residual daytime sedation - higher risk with longer-acting agents 1

If BzRAs must be used (after ramelteon/doxepin failure), the dosing must be reduced 1:

• Eszopiclone: 1 mg (not 2-3 mg)
• Zolpidem: 5 mg (not 10 mg) or 6.25 mg controlled-release
• Zaleplon: 5 mg (not 10 mg)
• Temazepam: 7.5 mg (not 15-30 mg)
• Triazolam: 0.125 mg (not 0.25 mg)

Emerging Evidence: Melatonin

Recent 2026 meta-analysis data 8 shows melatonin improves sleep quality specifically in hemodialysis patients, with improvements in global PSQI scores, sleep duration, sleep efficiency, and sleep disturbances. This represents the most recent and directly relevant evidence for this exact population. However, the 2017 AASM guideline 2 recommends against melatonin use due to variable product quality and limited efficacy data in general populations. Given the new dialysis-specific evidence, over-the-counter melatonin (2-5 mg) could be considered as an initial trial before prescription medications, acknowledging product quality variability.

What to AVOID

Absolutely contraindicated or not recommended 2, 1:

• Trazodone - despite common off-label use, AASM 2017 guidelines explicitly recommend AGAINST it 2, and it carries significant risks including orthostatic hypotension and cardiac effects 5
• Diphenhydramine and antihistamines - not recommended due to lack of efficacy/safety data and anticholinergic burden 2, 1
• Benzodiazepines not approved for insomnia (lorazepam, clonazepam) - higher risk profile
• Barbiturates and chloral hydrate - explicitly not recommended 1

Critical Caveats for Dialysis Patients

1. Sedation for procedures: Diazepam and midazolam are considered safe for conscious sedation in dialysis patients as they are hepatically metabolized with no dose adjustment needed 3

2. SSRIs for comorbid depression: If depression coexists, exercise caution with SSRIs in dialysis patients - trials show inconsistent benefits and increased GI adverse effects 9

3. Nonpharmacologic approaches should be emphasized: Cognitive behavioral therapy for insomnia (CBT-I) is first-line per multiple guidelines 1, 6 and particularly important in this high-risk patient to minimize polypharmacy

4. Address contributing factors:

   • Uremia-related symptoms
   • Restless legs syndrome (common in dialysis) - consider ropinirole or pramipexole 10
   • Depression/anxiety screening
   • Medication review for sleep-disrupting agents

Treatment Algorithm

1. First: Trial melatonin 2-5 mg or ramelteon 8 mg at bedtime
2. If sleep maintenance is the primary issue: Low-dose doxepin 3-6 mg
3. If ineffective after 1-2 weeks: Consider low-dose BzRA with appropriate elderly/renal dosing
4. Throughout: Implement sleep hygiene and pursue CBT-I if accessible
5. Monitor closely: Reassess every 2-4 weeks for efficacy, adverse effects, and need for continuation 1

The goal is the lowest effective dose for the shortest duration necessary, with regular attempts to taper when conditions allow 1.